CADTH

Background information for patients and health care providers on biosimilar drugs has been developed by the Canadian Agency for Drugs and Technologies in Health (CADTH), which is Canada’s independent health technology assessment agency.

Health Canada

Several biosimilar resources have been developed by Health Canada, which is the federal department that regulates the safety and efficacy of medicines in Canada.

IGBA and Biosimilars Canada

Biosimilars Canada and its partners with the International Generic and Biosimilar Medicines Association (IGBA) have developed educational materials on various aspects of biologic drugs, including biosimilar medicines.


The era of biological medicines

Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide, millions of patients have already benefited from approved biological medicines, but what exactly are they, and how are they produced?


Biological medicines ― the major social and economic challenges

The global spend on pharmaceuticals continues to increase. The use of biological medicines offers new treatment choices to patients, but at a high financial cost. What are the challenges faced by payers and physicians in preserving access to biological medicines within a financially constrained healthcare system?


Biosimilar medicines — rising to the cost challenge

Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar medicines are providing more cost-effective biological treatments, but what are biosimilar medicines, and how do they meet this challenge?


Biosimilar medicines — a commitment to scientific excellence

With biosimilar medicines, patients and healthcare providers benefit from high quality and efficacious therapeutic alternatives. But how are biosimilar medicines developed, and how is their efficacy and safety ensured?


The benefits of biosimilar medicines

Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?


Building on the experience and success of biosimilar medicines

Biosimilar medicines are increasingly becoming an integral part of modern healthcare systems, so what does the future hold?